Business · 29/04/2005Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for GEODON Patent Extension
Summary
The Food and Drug Administration has officially confirmed the regulatory review period for GEODON, a human drug product, in accordance with federal regulations, following a submission to the Director of Patents and Trademarks at the Department of Commerce.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →